These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17710400)

  • 1. In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia.
    Fiegl M; Zimmermann I; Lorenz I; Hiddemann W; Braess J
    Ann Hematol; 2008 Jan; 87(1):27-33. PubMed ID: 17710400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
    Valkov NI; Sullivan DM
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):48-62. PubMed ID: 9408961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
    Styczynski J; Wysocki M; Debski R; Czyzewski K; Balwierz W; Juraszewska E; Matysiak M; Malinowska I; Stanczak E; Sońta-Jakimczyk D; Szczepanski T; Wachowiak J; Konatkowska B; Balcerska A; Ploszynska A; Kowalczyk J; Stefaniak J; Badowska W; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M
    Neoplasma; 2005; 52(1):74-8. PubMed ID: 15739031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments in the treatment of acute myeloid leukemia: focus on topotecan.
    Kantarjian H
    Semin Hematol; 1999 Oct; 36(4 Suppl 8):16-25. PubMed ID: 10622225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cationic porphyrins and analogues as new DNA topoisomerase I and II inhibitors.
    Shuai L; Wang S; Zhang L; Fu B; Zhou X
    Chem Biodivers; 2009 Jun; 6(6):827-37. PubMed ID: 19551725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.
    Saraiya B; Gounder M; Dutta J; Saleem A; Collazo C; Zimmerman L; Nazar A; Gharibo M; Schaar D; Lin Y; Shih W; Aisner J; Strair RK; Rubin EH
    Anticancer Drugs; 2008 Apr; 19(4):411-20. PubMed ID: 18454051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
    Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
    Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia.
    Hubeek I; Peters GJ; Broekhuizen R; Zwaan CM; Kaaijk P; van Wering ES; Gibson BE; Creutzig U; Janka-Schaub GE; den Boer ML; Pieters R; Kaspers GJ
    Haematologica; 2006 Jan; 91(1):17-23. PubMed ID: 16434366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity.
    Bonci D; Musumeci M; Coppola V; Addario A; Conticello C; Hahne M; Gulisano M; Grignani F; De Maria R
    Haematologica; 2008 Dec; 93(12):1899-902. PubMed ID: 18838478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase II alpha expression in acute myeloid leukaemia and its relationship to clinical outcome.
    McKenna SL; West RR; Whittaker JA; Padua RA; Holmes JA
    Leukemia; 1994 Sep; 8(9):1498-502. PubMed ID: 8090029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
    Perl AE; Kasner MT; Tsai DE; Vogl DT; Loren AW; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Frey NV; Nasta SD; Hexner EO; Dierov JK; Swider CR; Bagg A; Gewirtz AM; Carroll M; Luger SM
    Clin Cancer Res; 2009 Nov; 15(21):6732-9. PubMed ID: 19843663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia.
    Styczynski J; Wysocki M; Dluzniewska A; Juraszewska E; Balwierz W; Czyzewski K; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M; Kowalczyk J; Stefaniak J; Badowska W; Sonta-Jakimczyk D; Szczepanski T; Matysiak M; Stanczak E; Malinowska I; Wachowiak J; Konatkowska B; Gil L; Balcerska A; Kapuscinska L; Szczepanek J; Kolodziej B; Rafinska B; Kubicka M
    Anticancer Res; 2008; 28(3B):1927-31. PubMed ID: 18630483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of cell viability and apoptosis with clinical remission following induction chemotherapy in ALL and AML.
    Bhushan B; Ahuja D; Verma S; Saluja S; Siddiqui S; Kapur S
    J Exp Clin Cancer Res; 2007 Sep; 26(3):313-21. PubMed ID: 17987789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death.
    Weidenaar AC; de Jonge HJ; Fidler V; ter Elst A; Meeuwsen-de Boer T; Douwes J; Bouma-ter Steege JC; Hählen K; Kamps WA; de Bont ES
    Anticancer Drugs; 2008 Jan; 19(1):45-54. PubMed ID: 18043129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HA14-1, a small molecule inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells.
    Oliver L; Mahé B; Gréé R; Vallette FM; Juin P
    Leuk Res; 2007 Jun; 31(6):859-63. PubMed ID: 17224180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia.
    Jenkins C; Hewamana S; Gilkes A; Neelakantan S; Crooks P; Mills K; Pepper C; Burnett A
    Br J Haematol; 2008 Dec; 143(5):661-71. PubMed ID: 19036014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
    Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
    Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory activities against topoisomerase I and II by polyhydroxybenzoyl amide derivatives and their structure-activity relationship.
    Abdel-Aziz M; Matsuda K; Otsuka M; Uyeda M; Okawara T; Suzuki K
    Bioorg Med Chem Lett; 2004 Apr; 14(7):1669-72. PubMed ID: 15026047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.